Author Question: A certain isotope has a half-life of 32.4 hr and a relative biological effectiveness of 3.50. A ... (Read 81 times)

jrubin

  • Hero Member
  • *****
  • Posts: 552
A certain isotope has a half-life of 32.4 hr and a relative biological effectiveness of 3.50. A sample of this isotope initially delivers an absorbed dose of 0.240 Gy to 250 g of tissue.
 
  (a) What was the initial equivalent dose to the tissue in rem and in sieverts?
  (b) How many joules of energy did the 250-g sample initially receive from the isotope?
  What will be an ideal response?

Question 2

Carbon-14 has a half-life of 5730 y. A sample of wood has been recovered by an archaeologist. The sample is sent to a laboratory, where it is determined that the activity of the sample is 0.144 Bq/g.
 
  By comparing this activity with the activity of living organic matter,
  0.230 Bq/g, the scientist determines how old the wood sample is, or more precisely, when the tree that the sample came from died. How old is the sample of wood?
  A) 3870 y
  B) 4250 y
  C) 4590 y
  D) 2630 y
  E) 2940 y



prumorgan

  • Sr. Member
  • ****
  • Posts: 326
Answer to Question 1

Answer: (a) 84 rem, 0.84 Sv (b) 0.060 J

Answer to Question 2

Answer: A



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Long-term mental and physical effects from substance abuse include: paranoia, psychosis, immune deficiencies, and organ damage.

Did you know?

Less than one of every three adults with high LDL cholesterol has the condition under control. Only 48.1% with the condition are being treated for it.

Did you know?

Vaccines cause herd immunity. If the majority of people in a community have been vaccinated against a disease, an unvaccinated person is less likely to get the disease since others are less likely to become sick from it and spread the disease.

Did you know?

After 5 years of being diagnosed with rheumatoid arthritis, one every three patients will no longer be able to work.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library